Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
NCT07266441 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refractory' if does not respond to treatment) who have received at least 3 prior lines of therapy.
Conditions Studied
Interventions
- DRUG JNJ-79635322
Study Locations (20)
Other
- Ha'Emek Medical Center — Afula
- Samson Assuta Ashdod University Hospital — Ashdod
- Hillel Yaffe Medical Center — Hadera
- Hadassah Medical Center — Jerusalem
- Rabin Medical Center — Petah Tikva
California
- City of Hope — Duarte
- City of Hope Orange County Lennar Foundation Cancer Center — Irvine
- Cancer and Blood Specialty Clinic — Los Alamitos
Georgia
- Emory University — Atlanta
- Northside Hospital Cancer Institute — Atlanta
Iowa
- University of Iowa — Iowa City
- Mission Cancer Blood — Waukee
Texas
- MD Anderson Cancer Center — Houston
- Oncology Consultants Texas — Houston
Florida
- Cancer Specialists of North Florida — Jacksonville
Illinois
- Cancer Care Specialists of Central Illinois — O'Fallon
New Jersey
- Rutgers Cancer Institute — New Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2026-02-08 |
| Est. Completion | 2028-12-12 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07266441
The ClinicalTrials.gov registry entry for NCT07266441 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 157 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 442 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 1 intervention — of which JNJ-79635322 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT07266441 reports 20 study locations spanning 11 distinct geographic areas — top geographies include Other, California, Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT07266441 about?
NCT07266441 is a clinical study titled "A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma". The purpose of this study is to evaluate how well JNJ-79635322 works (efficacy) in participants with Relapsed or Refractory Multiple Myeloma (RRMM; a cancer that forms in a type of white blood cells called a plasma cell. Cancer is called relapsed if it comes back after treatment and is called 'refra...
What is the current status of trial NCT07266441?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 157 participants. The study started on 2026-02-08. Estimated completion is 2028-12-12.
What conditions does trial NCT07266441 study?
This clinical trial studies the following conditions: Multiple Myeloma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT07266441?
The interventions under investigation include: JNJ-79635322 (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT07266441?
This trial is sponsored by Janssen Research & Development, which has 442 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT07266441 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.